Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample …
Full AZTA analysis →
Competitive advantage assessment
Key strengths
Durable Capital ReturnsROIC durability is strong (score 0.95). Consistent returns confirm the moat is not eroding.
Where AZTA ranks in Medical Instruments & Supplies
Azenta, Inc. ranks #22 of 62
scored companies in Medical Instruments & Supplies by moat score — the top 35%.
The widest moat in the group is Intuitive Surgical, Inc. (ISRG)
at 86/100.
Moat scores for companies ranked near AZTA in Medical Instruments & Supplies
How AZTA scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 54
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 71
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 64
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 55
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 83
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 44
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Azenta, Inc. (AZTA) scores 61 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #22 of 62 scored companies in Medical Instruments & Supplies, the top 35%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is Capital Structure & Resilience (83/100) and its weakest is Growth Durability (44/100).
How does Azenta, Inc. compare with other Medical Instruments & Supplies companies?
Azenta, Inc. ranks #22 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are Bausch + Lomb Corporation (BLCO) at 61 just above it and Envista Holdings Corporation (NVST) at 60 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.
Why is Azenta, Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Azenta, Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and AZTA scores: Pricing Power & Consumable Moat (54), R&D Pipeline & Capital Returns (71), FCF Quality & Cash Conversion (64), Commercial Execution (55), Capital Structure & Resilience (83), Growth Durability (44). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.